PropertyValue
?:abstract
  • divInfection with SARS-CoV-2 has resulted in COVID-19 pandemic and infected more than 5/divdivmillion individuals with around 0 35 million deaths worldwide till May 2020 end Several/divdivefforts are on in search of therapeutic interventions, but the preferred way is drug/divdivrepurposing due to the feasibility and urgency of the situation To select and prioritize/divdivapproved antiviral drugs and drug combinations for COVID-19, 61 antiviral drugs having/divdivproven safety profile in humans were subjected to virtual screening for binding to three/divdivselect targets namely human angiotensin-converting enzyme receptor-2 receptor-binding/divdivdomain (hACE-2) involved in virus entry, SARS-CoV-2 RNA dependent RNA polymerase/divdiv(RdRp) responsible for viral RNA replication and SARS-CoV-2 main protease (MPro) causing/divdivproteolytic processing of viral polyprotein slab Targeting multiple ‘disease pathogenesis/divdivspecific proteins’ within a close network of interaction or having dependent functionality can/divdivprovide effective intervention Ledipasvir, Daclatasvir, Elbasvir, Paritaprevir, Rilpivirine and/divdivIndinavir were identified as candidate drugs of interest for COVID-19 based on a derived/divdivcombined activity score, pharmacokinetic and pharmacodynamic parameters Ledipasvir and/divdivDaclatasvir and their approved marketed combination with Sofosbuvir emerged as leading/divdivcandidate drugs/drug combinations for SARS-CoV-2 These candidates have the potential/divdivfor the antiviral activity for SARS-CoV-2 infection better than the investigational drug/divdivRemdesivir and other antiviral drugs/drug combinations being evaluated These/divdivdrugs/combinations merit systematic fast track preclinical and clinical evaluation for COVID-/divdiv19 management The present work brings back attention to the potential usefulness of/divdivapproved antiviral drugs/drug combinations, commonly available with established safety/divdivprofile, currently not in focus for COVID-19 It provides a rationale based approach for the/divdivselection of drugs with potential antiviral activity against SARS-CoV-2 highlighting the/divdivdesired properties /div
is ?:annotates of
?:creator
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Rationale Based Selection and Prioritization of Antiviral Drugs for COVID-19 Management
?:type
?:who_covidence_id
  • #317
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/DB01221_interactsWith_DB08907>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/DB01221_interactsWith_DB08907>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all